CD20-directed Antibody Interactions [MoA] class drugs

13 results
  • briumvi - ublituximab injection, solution, concentrate

    (Ublituximab)
    Tg Therapeutics, Inc.
    BRIUMVI treats relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
  • columvi - glofitamab concentrate

    (Glofitamab)
    Genentech, Inc.
    Columvi treats adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL, NOS) or large B-cell lymphoma arising from follicular lymphoma, after two or more prior lines of systemic therapy.
  • epkinly - epcoritamab - bysp injection, solution

    (Epcoritamab-Bysp)
    Genmab Us, Inc.
    Epkinly treats adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma after 2+ prior therapies. Also indicated for relapsed or refractory follicular lymphoma (FL), with lenalidomide and rituximab or as monotherapy after 2+ prior therapies.
  • gazyva - obinutuzumab injection, solution, concentrate

    (Obinutuzumab)
    Genentech, Inc.
    GAZYVA treats previously untreated chronic lymphocytic leukemia (with chlorambucil), relapsed or refractory follicular lymphoma after rituximab-containing regimens (with bendamustine), previously untreated stage II bulky, III, or IV follicular lymphoma (with chemotherapy), and active lupus nephritis in adults on standard therapy.
  • kesimpta - ofatumumab injection, solution

    (Ofatumumab)
    Novartis Pharmaceuticals Corporation
    Kesimpta treats relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
  • ocrevus - ocrelizumab injection

    (Ocrelizumab)
    Genentech, Inc.
    Ocrevus treats relapsing forms of MS (including clinically isolated syndrome, relapsing-remitting, and active secondary progressive disease) and primary progressive MS in adults.
  • rituxan - rituximab injection, solution

    (Rituximab)
    Genentech, Inc.
    Rituxan treats Non-Hodgkin's Lymphoma (adults and pediatric patients 6+ months), Chronic Lymphocytic Leukemia, moderately-to-severely active Rheumatoid Arthritis unresponsive to TNF antagonists, Granulomatosis with Polyangiitis and Microscopic Polyangiitis (ages 2+), and moderate-to-severe Pemphigus Vulgaris in adults.